Presentation document

Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2027

November 10, 2026

KYORIN Pharmaceutical Co., Ltd.

- **Outline of Consolidated Financial Results**
- **Revision of Consolidated Financial Forecast**
- **Medium-Term Business Plan of “Vision 110 –Stage 2–”**

Highlights of Business Performance : Vs Forecast

(JPY billions)

	FY2026 1H Forecast (announced on May 12, 2026)	FY2026 1H Actual	Vs Forecast	
			Change	Achievement rate (%)
Net sales	57.8	**57.5**	**−0.3**	**99.5**
New drugs, etc. (Japan)	40.7	**40.4**	**−0.3**	**99.2**
New drugs (Overseas)	0.2	**0.2**	**0**	**118.4**
Generic drugs	16.7	**16.9**	**+0.2**	**101.1**
Cost of sales	—	**35.1**	**—**	**—**
Gross profit	—	**22.4**	**—**	**—**
SG&A (R&D expenses)	— (5.1)	**22.1 (4.5)**	**— (−0.6)**	**— (87.5)**
Operating profit	−0.3	**0.3**	**+0.6**	**—**
Ordinary profit	−0.1	**0.7**	**+0.8**	**—**
Profit attributable to owners of parent	0	**−1.6**	**−1.6**	**—**

■Net sales

New drugs, etc. (Japan) : −0.3 billion yen

[Upside Factors] Outperformance of Beova

[Downside Factors] Underperformance of Lasvic and Mucodyne

Generic drugs : +0.2 billion yen

[Upside Factors] Outperformance of Authorized Generic (AG)

■SG&A

R&D expenses : −0.6 billion yen

■Extraordinary loss

Loss on the transfer of the generic drug business : 2.5 billion yen

Highlights of Business Performance : Year on year

(JPY billions)

	FY2025 1H	FY2026 1H	Year on year	
			Change	Change (%)
Net sales	58.7	**57.5**	**－1.2**	**－2.1**
New drugs, etc. (Japan)	41.4	**40.4**	**－1.0**	**－2.5**
New drugs (Overseas)	0.5	**0.2**	**－0.3**	**－53.0**
Generic drugs	16.8	**16.9**	**＋0.1**	**＋0.4**
Cost of sales	33.8	**35.1**	**＋1.3**	**＋3.8**
Gross profit	24.9	**22.4**	**－2.5**	**－10.1**
SG&A **（R&D expenses）**	23.5 (5.4)	**22.1** **(4.5)**	**－1.4** **(－0.9)**	**－6.2** **(－18.0)**
Operating profit	1.4	**0.3**	**－1.1**	**－77.6**
Ordinary profit	1.6	**0.7**	**－0.9**	**－56.4**
Profit attributable to owners of parent	1.5	**－1.6**	**－3.1**	**—**

■Net sales

New drugs, etc. (Japan) : －1.0 billion yen

[Factor of increase] Beova sales grew

[Factor of decrease] Impact of NHI drug price revision (Kyorin Pharmaceutical: 4% range)

Impact of entry of generic competition for Desalex

New drugs (Overseas) : －0.3 billion yen

[Factor of decrease] Rebound decline in gatifloxacin-related revenue

Generic drugs : ＋0.1 billion yen

[Factor of Increase] Contributions from AGs and new generic launches in FY2026

■SG&A

R&D expenses : －0.9 billion yen

Absence of upfront payments recorded in the previous period (KRP-A225) 1.5

SG&A (excluding R&D expenses) : －0.5 billion yen

Cost reduction, increase in license fees

■Extraordinary loss

Loss on the transfer of the generic drug business : 2.5 billion yen

Mainstay Product Sales Update

(JPY billions)

		FY2026 1H Forecast (announced on May 12, 2026)	FY2026 1H Actual	Vs Forecast		FY2025 1H	Year on year	
				Change	Achievement rate (%)		Change	Change(%)
New drugs, etc. (Japan)	Beova (Kyorin)	12.9	**14.4**	+1.5	111.3	12.3	+2.1	+17.0
	Lasvic	3.9	**3.5**	−0.4	90.4	3.5	0	+0.1
	Fultiform	5.9	**5.9**	0	99.9	6.3	−0.4	−6.6
	Lyfnua	0.5	**0.4**	−0.1	83.3	0.5	−0.1	−10.6
	Mucodyne	2.4	**1.9**	−0.5	80.4	2.0	−0.1	−2.6
	Pentasa	5.1	**5.3**	+0.2	103.3	6.3	−1.0	−15.9
	Desalex	1.6	**1.6**	0	100.6	3.7	−2.1	−56.1
	Kipres	0.4	**0.6**	+0.2	139.7	0.9	−0.3	−40.4
	Milton	0.9	**0.8**	−0.1	89.0	0.9	−0.1	−14.3
	Rubysta	0.3	**0.3**	0	115.5	0.4	−0.1	−15.0
Generic drugs	Montelukast tablets “KM”	4.3	**4.7**	+0.4	110.1	4.4	+0.3	+7.7
	Mometasone Nasal 50μg “KYORIN”	1.0	**1.0**	0	95.9	1.1	−0.1	−14.4

Revision of Consolidated Financial Forecast for FY2026

(JPY billions)

	FY2025 Actual	FY2026 (Original forecast)	**FY2026 (Revised forecast)**	**Change**
Net sales	126.3	121.8	**121.8**	**0**
New drugs, etc. (Japan)	87.1	83.5	**83.5**	**0**
New drugs (Overseas)	0.7	0.3	**0.3**	**0**
Generic drugs	38.5	37.9	**37.9**	**0**
Cost of sales	74.6	—	**—**	**—**
SG&A (R&D expenses)	48.1 (12.1)	— (9.3)	**— (16.2)**	**— (+6.9)**
Operating profit	3.6	2.0	**−4.9**	**−6.9**
Ordinary profit	4.0	2.3	**−4.6**	**−6.9**
Profit attributable to owners of parent	3.4	1.5	**−5.1**	**−6.6**

■R&D Expenses

Upfront payment under the license agreements

- **ARDS treatment candidate EB05 : USD 12 million**
- **Expected upfront payment for a highly likely in-licensing agreement**

■Extraordinary loss

Loss on the transfer of the generic drug business : 2.5 billion yen

Forecast of Mainstay Products Sales

*Unchanged from the original forecast

(JPY billion yen)

		FY2025 Actual	**FY2026 Forecast**	Year on year	
				Change	Change (%)
New drugs, etc. (Japan)	**Beova (Kyorin)**	25.8	**26.7**	+0.9	+3.3
	Lasvic	7.3	**9.0**	+1.7	+23.5
	Fultiform	12.8	**12.3**	−0.5	−3.9
	Lyfnua	0.9	**1.0**	+0.1	+7.7
	Mucodyne	3.7	**5.4**	+1.7	+46.2
	Pentasa	12.3	**10.2**	−2.1	−17.4
	Desalex	10.2	**2.3**	−7.9	−77.5
	Kipres	2.2	**1.0**	−1.2	−54.1
	Milton	1.8	**1.8**	0	−0.6
	Rubysta	0.8	**0.7**	−0.1	−11.4
Generic drugs	**Montelukast tablets “KM”**	11.4	**10.1**	−1.3	−11.7
	Mometasone Nasal 50μg “KYORIN”	4.5	**3.9**	−0.6	−13.8

Positioning of "Vision 110 -Stage2-" and Five Business Strategies

Growth and Leap forward

Stage3: FY2030-FY2032 and beyond

Harvesting results and achieving sustainable growth

Establishing a revenue base through growth investment

Stage2: FY2026-FY2029

[Statement]

Aggressive Investment for Sustainable Growth

- **Top priority on securing in-licensed products as sustainable growth engines**
- **While aggressive investments (milestone payments, etc.) may lead to a challenging financial and profit situation, we will proceed with firm conviction to ensure mid-to-long-term sustainable growth**


Five Business Strategies

1. **Expansion of development pipeline through in-licensing**
2. **Strengthening drug discovery capability to create high-value new drugs that meet medical needs**
3. **Maximizing the market penetration of new drugs**
4. **Promoting healthcare-related businesses that have synergies with the new drugs business**
5. **Building a sustainable corporate foundation**

Transformation of the business structure

Stage1: FY2023-FY2025

Establishing a structure to strengthen drug discovery and expanding the development pipeline



Stage3 Harvesting

Stage2 Sowing and Nurturing

Stage1 Soil preparation and sowing

Stage 2 Licensing target: Achieve cumulative 10+ licenses acquired

- Expand broad licensing activities across all modalities and disease areas
- Acquire licensed products rapidly and reliably by utilizing all possible means

FY2026 In-Licensing Achievements (As of Nov 9) : 2 Licenses acquired

- **Edesa Biotech, Inc. : ARDS treatment candidate EB05**
- **Santen Pharmaceutical Co., Ltd. : Alesion Eyelid Cream 0.5%**

Outlook

Negotiating in-licensing for late-stage pipeline assets and commercial partnerships, aiming to execute agreements for multiple products in 2H FY2026

About EB05 – ARDS treatment candidate

Generic Name	Paridiprubart
Target Indication	ARDS (Acute Respiratory Distress Syndrome)
Mechanism of Action	Monoclonal antibody targeting TLR4 (selectively inhibits TLR4 signaling to suppress systemic inflammation)
Dosage Form/Usage	Intravenous infusion (single dose)
Development Status	Targeting Phase 3 trial initiation in Japan in FY2028
Financial Terms	Upfront: USD 12million Development and commercial milestones: Up to USD 134 million Sales royalties

Development of an innovative therapeutic agent for ARDS demonstrating a reduced risk of mortality (Launch targeted during “Stage3”)

About EB05 – ARDS treatment candidate

ARDS

A clinical syndrome characterized by the rapid onset of severe, life-threatening respiratory failure

Prognosis: Poor; Mortality rate: 30–58%*

Patient population: >10,000 patients/year (Internal estimate)


Current management

Respiratory management including mechanical ventilation

Pharmacotherapy: Low-dose corticosteroids to suppress inflammation

Currently, no effective pharmacotherapy has been established to reduce mortality risk

ARDS Onset



ARDS represent unmet medical need with no effective pharmaceutical currently available

*ARDS Clinical Practice Guidelines 2016

EB05 Development Status (Conducted by Edesa)

Phase 3 Clinical trial in the patients with ARDS associated with SARS-CoV-2 infection, randomized , double-blind, placebo controlled

Efficacy

- **Statistically significant reduction in 28- and 60-day mortality in the critically ill patients receiving invasive mechanical ventilation**
  - ✓ Mortality at Day 28 (n=104): EB05+SOC 39%, Placebo + SOC 52% (p<0.001)
  - ✓ Mortality at Day 60 (n=104): EB05+SOC 46%, Placebo + SOC 59% (p=0.003)

SOC : Standard of Care

- **Estimated proportion achieving at 2-pt reduction* in WCSSS score(Day 28)：EB05 38%, Placebo 27% (p<0.05)**

*Implies ICU discharge and independence from IMV or organ support

[Exploratory analyses]

- **Showed treatment effect in clinically relevant subgroups, including patients with sepsis, pneumonia, and acute kidney injury (AKI)**
- **Showed mortality reduction across a broad patient population (n=278), including mild-to-moderate patients not requiring intubation or mechanical ventilation**

Safety

Well-tolerated, favorable safety profile


A new global Phase 3 trial is planned to pursue approval for general ARDS (timing TBD)

Development of an innovative therapeutic agent for ARDS demonstrating a reduced risk of mortality

Reference: Phase 3 Clinical Data Announced by Edesa

Phase 3 Results – Primary Endpoint 28-Day Mortality

Paridiprubart Met Primary and Secondary Endpoints with Statistical Significance



* Estimated risk of mortality using multivariate logistic regression derived risk differences (95% confidence interval). Final Phase 3 protocol comprised ICU patients with ARDS (mild/moderate/severe); Invasive Mechanical Ventilation and/or patients receiving organ support/ECMO; Company opted to truncate enrolment for business reasons: 104 Patients enrolled in per protocol population; 278 patients enrolled in intent-to-treat and safety populations. Subject randomized 1:1 placebo plus standard of care (SOC) treatment or paridiprubart + SOC.

Edesa Biotech

Summary of Phase 3 Results

28-Day Mortality Rate: Paridiprubart had a relative reduction in the risk of death of 25% compared to placebo

60-Day Mortality Rate: A durable survival benefit was also demonstrated. Paridiprubart had a relative reduction in the risk of death of 22% vs. placebo

Clinical Improvement at Day 28: Paridiprubart showed a 41% higher relative rate of clinical improvement, meaning patients no longer required IMV and/or organ support


Other Signals: Paridiprubart reduced mortality in a population that included patients not on IMV

Safety Population: Favorable safety profile in 278 subjects

Edesa Biotech Corporate Overview

[source] Edesa's ccorporate presentation,
https://www.edesabiotech.com/wp-content/uploads/2026/10/EdesaBiotech-EDSA-Presentation-Oct2026.pdf

Reference: Phase 3 Clinical Data Announced by Edesa



[source] Edesa's ccorporate presentation,
https://www.edesabiotech.com/wp-content/uploads/2026/10/EdesaBiotech-EDSA-Presentation-Oct2026.pdf

Alesion Eyelid Cream 0.5%

July 2026 **Entered into Joint marketing agreement with Santen**

August 2026 **Commenced promotion by KYORIN (excluding ophthalmology)**

Financial Terms	• No upfront payment • Receive co-promotion fees based on sales and the number of details
Product Features	• Cream formulation applied once daily to the periocular area • Expected to improve patient adherence through treatment compliance and reduced burden
Initiatives	• Allocate sales resources to otolaryngology and internal medicine, leveraging a strong sales platform • Conduct year-round promotion, not limited to the pollen allergy season • Promote proper medication instructions to ensure drug efficacy

Aim to support all day comfort for patients, advancing the treatment concept of proactive instillation



4 times / day	2 times / day	1 time / day
Alesion Ophthalmic Solution 0.05%	Alesion LX Ophthalmic Solution 0.1%	Alesion Eyelid Cream 0.5%

Image courtesy of Santen

Delivering an itch-free life to allergic conjunctivitis patients

Status of R&D Pipeline

※Updated (As of November 9, 2026)


	Development code	Ph1	Ph2	Ph3	Application	Approval / Launch
Respiratory	KRP-S124※					
	EB05※			In preparation		
Urology	KRP-114VP					
Autoimmune disease	KRP-A225	Overseas（Hinge Bio）				
Pain	KRP-126※					

DTx


	Development code	Research / Development	Pivotal study	Application	Approval / Launch
Otolaryngology	KRP-DT123				
Respiratory	KRP-DC125				

	Compound/Code	Licensee	Stage	Feartures
Licensed Compound	KRP-M223	Novartis	Pre-clinical	●MRGPRX2 antagonist ●Target: allergic and inflammatory diseases involving mast cells

[Mainstay products] Beova (Therapeutic agent for OAB)



Copyright © 2026 IQVIA. Calculated based on JPM 2022- 2026 (Apr-Sep), reprinted with permission



Market

- OAB Market : ＋4.9%*1
- Market expansion of β3 receptor antagonist*1

Medium to long term market outlook

- Number of OAB patients tend to increase
- Despite the impact of the NHI drug price revision, the Market for β3 adrenergic receptor is expanding

Initiative FY2026

- Expand patient share in general internal medicine
- DTC: initiative to encourage medical consultation
- Disseminating new clinical evidence

Status in FY2026 1H


- No.1 in OAB market sale*2
- No.1 share of OAB patients and rate of new patients acquisition*2

[NHI drug price revision : －4.24% (Apr 2026)]


*1: Copyright © 2026 IQVIA. Calculated based on JPM Apr-Sep 2025, Apr-Sep 2026, reprinted with permission

*2: Combined total with partner company
Copyright © 2026 IQVIA. Calculated based on JPM Apr-Sep 2026, reprinted with permission
Calculated based on IQVIA Rx .Sep 2026, reprinted with permission

[Mainstay products] Lasvic (New quinolone synthetic antibacterial agent)



Copyright © 2026 IQVIA. Calculated based on JPM 2022- 2026 (Apr-Sep), reprinted with permission



Market

- Oral antimicrobial : −13.1%*1
- Lower-than-usual incidence of respiratory infections

Medium to long term market outlook

- Number of OAB patients tend to increase
- Expect to tend to decrease in oral antimicrobial market due to prevent infection / appropriate use against AMR

Initiative FY2026

- Promote treatment and therapeutic drug selection in accordance with each guideline, while driving prescriptions across high-volume indications such as pharyngitis, laryngitis, sinusitis, and bronchitis, in addition to pneumonia
- Clearly define the distinctiveness and novel positioning of Lasvic

Status in FY2026 1H

- Steady growth in market share : 25 1H 9.7% → 26 1H 10.8% *1
- Achieved No.1 of sales share in oral NQ market*1

[NHI drug price revision : −2.77% (tab), −0.96% (iv) (Apr 2026)]

*1: Copyright © 2026 IQVIA. Calculated based on JPM Apr-Sep 2025, Apr-Sep 2026, reprinted with permission

[Mainstay products] Maximizing Penetration of SIRTURO

* Subject to regulatory approval for additional indications

- **Creating prescription opportunities by leveraging broad coverage in HP and GP markets, which is Lasvic's activity base.**
- **Deploying promotional activities equivalent to those of a new product launch.**
- **Establishing a position as a treatment for treatment-refractory *Mycobacterium avium* complex-lung disease (MAC-LD) following approval for the additional indication.**


Multidrug-Resistant Tuberculosis: MDR-TB

Disease	Pulmonary tuberculosis caused by Mycobacterium tuberculosis strains resistant to isoniazid (INH) and rifampicin (RFP).
Patient Number	6,423 newly registered smear-positive pulmonary TB patients; 45 multidrug-resistant TB patients (resistant to both INH and RFP).
Drug Price	¥21,636.50 (as of April 2026).

Pulmonary MAC Disease (MAC-LD, Filed, Janssen pharma)

Disease	MAC-LD: A chronic infectious disease caused by *Mycobacterium avium* complex (MAC) infecting the lungs
Patient Number	Estimated at over 100,000; the number of patients is on an upward trend.

- Commencing promotional activities for multidrug-resistant tuberculosis (MDR-TB) in June 2026, aiming to increase product awareness.
- Following approval of the additional indication for treatment-refractory MAC-LD, sales for both indications will be recognized as our revenue.
- Establishing internal framework for sales activities following approval of the additional indications




Maximizing the market penetration of new drugs

▶ Focus on maximizing the penetration of the three mainstay products-Beova and Lasvic, plus SIRTURO

	Stage2 Exit Targets(FY2029)	Initiatives to maximize penetration
Beova 	¥27.0B+	● Target: 60% patient share in the OAB market (Current: 48.7%) ● Identifying potential patients through disease awareness campaigns. ● Increasing penetration in general internal medicine in addition to urology
Lasvic 	¥12.0B+	● Target: 50% sales share in the oral quinolone antibacterial market (Current: 41.7%) ● Securing prescriptions through guideline penetration (promoting appropriate use) ● Establishing a "first-choice" position for elderly patients and those with underlying respiratory or ENT infections.
SIRTURO 	¥20.0B+ at an early stage	● Creating prescription opportunities by leveraging broad coverage in HP and GP markets, which is Lasvic's activity base. ● Deploying promotional activities equivalent to those of a new product launch. ● Establishing a position as a treatment for MAC-LD following approval for the additional indication.

Sales of Three Core Products



*1: Copyright © 2026 IQVIA. Calculated based on JPM 2026 Mar. MAT, reprinted with permission
*2: Subject to regulatory approval for additional indications

Transfer of Generic Drug Business

Purpose of the Business Transfer

KYORIN Optimize the business portfolio and focus resources on the new drug business

Society Contribute to the stable supply of high-quality, affordable generic drugs in Japan

[Target Business]

KYORIN Rimedio Co., Ltd. (excluding authorized generic business)
Takaoka and Inami Plants of KYORIN Pharmaceutical


[Transferee]

Name : Pharmatech Co-creation Platform, Inc. (PCPI)
Shareholders : Daito, Meiji Seika Pharma, DBJ

[Schedule]

Definitive Agreement : Sep. 30, 2026
Share Transfer : Apr. 1, 2027 (planned)

Scheme for the Transfer of Generic Drug Business



1. Transfer the Takaoka and Inami Plants to KYORIN Rimedio through an absorption-type company split

2. Transfer the authorized generic business to KYORIN Pharmaceutical Group Facilities through an absorption-type company split

3. Transfer all shares of KYORIN Rimedio to PCPI

Execution of Growth Investments in Stage2

Establishing a revenue base through growth investment | Stage2: FY2026-FY2029

[Statement]

Aggressive Investment for Sustainable Growth

- **Top priority on securing in-licensed products as sustainable growth engines**
- **While aggressive investments (milestone payments, etc.) may lead to a challenging financial and profit situation, we will proceed with firm conviction to ensure mid-to-long-term sustainable growth**

Five Business Strategies

1. **Expansion of development pipeline through in-licensing**
2. **Strengthening drug discovery capability to create high-value new drugs that meet medical needs**
3. **Maximizing the market penetration of new drugs**
4. **Promoting healthcare-related businesses that have synergies with the new drugs business**
5. **Building a sustainable corporate foundation**

Sources of Funds for Growth Investment

- **Utilization of financial leverage**
- **Proceeds from the transfer of the generic drug business**
- **Optimization of working capital**
- **Reduction of strategic shareholdings**

Growth Investment (In-licensing)

FY2026 (as of November 9) 2 Licenses acquired	**ARDS treatment EB05** **Alesion Eyelid Cream 0.5%**
Second half of FY2026	**Aiming to execute agreements for multiple products**

Steadily Execute Growth Investments for Sustainable Growth

● Disclaimer

This material contains performance forecasts, goals and plans, and other forward-looking statements related to the Group. These statements are based on the judgment of the Group's assumptions and outlooks based on the information and forecasts available at the time of preparation of this material, and contain known or unknown risks and uncertainties. Therefore, due to various factors that may occur, the actual performance, progress / success / failure of the development and other insights may differ significantly from the description. It also contains information about medicines (including those under development), but the description is not for the purpose of advertising or medical advice.


Kyorin